肿瘤标志物及其在腹部和盆腔恶性肿瘤影像检查中的应用
本文综述了放射科医生关注的常见肿瘤标志物(CEA、LDH、PSA、β-hCG、CA 19-9、AFP、CA 125)及其相关的恶性和非恶性病变,并展示了本院的病例示例。文章指出肿瘤标志物在筛查、鉴别诊断、风险评估、预后、治疗反应和疾病状态监测中有广泛用途,但标志物与相关病变之间存在显著重叠,尽管影像特征有提示性,确立鉴别诊断对放射科医生仍可能具有挑战性。
要点
- 肿瘤标志物可用于筛查、鉴别诊断、风险评估、预后、治疗反应及疾病监测,但标志物与病变间存在显著重叠。
- 放射科医生需熟悉CEA、LDH、PSA、β-hCG、CA 19-9、AFP、CA 125等常见标志物及其对应病变。
- 尽管影像特征有提示性,结合肿瘤标志物确立鉴别诊断仍可能具有挑战性。
临床应用与阅片要点
- 放射科医生应了解CEA、LDH、PSA、β-hCG、CA 19-9、AFP、CA 125等常见肿瘤标志物及其相关的恶性和非恶性病变。
- 影像检查发现可疑腹部或盆腔病变时,可结合肿瘤标志物信息辅助鉴别诊断,但需注意标志物与病变之间存在显著重叠。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The utility of tumour biomarkers has increased considerably in the era of personalised medicine and individualised therapy in oncology. Biomarkers may be prognostic or predictive, and only a handful of markers are currently US Food and Drug Administration (FDA)-approved for clinical use. Tumour markers have a wide array of uses such as screening, establishing a differential diagnosis, assessing risk, prognosis, and treatment response, as well as monitoring disease status. Major overlap exists between biomarkers and their associated pathologies; therefore, despite suggestive imaging features, establishing a differential diagnosis may be challenging for the radiologist. We review common biomarkers that are of interest to radiologists such as carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH), prostate-specific antigen (PSA), beta human chorionic gonadotropin (β-hCG), carbohydrate antigen 19-9 (CA 19-9), alpha fetoprotein (AFP), and carbohydrate or cancer antigen 125 (CA 125), as well as their associated malignant and non-malignant pathologies. We also present relevant case examples from our practice.
引用
- Lahoud RM, O'Shea A, El-Mouhayyar C, et al. Tumour markers and their utility in imaging of abdominal and pelvic malignancies. Clin Radiol. 2020. PMID: 32861463. doi:10.1016/j.crad.2020.07.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。